Board of Directors

Oran Muduroglu

Chairman

Over 25 years of healthcare industry experience. Oran is a recognised leader in healthcare technology and has spearheaded several start-ups for advanced imaging solutions and was co-founder of Stentor, that was acquired by Philips. He’s held leadership roles and led business projects for Verily, Medicalis, and Siemens, among others.

Matthew Frohn

Longwall Venture Partners

Matthew has over twenty years’ experience as a life science venture investor. As co-founder of Longwall Venture Partners, he has been involved as investor and board director in a range of healthcare and life science technology businesses including medical devices, molecular diagnostics, drug delivery systems, discovery tools and vaccines. He has a D.Phil in Biochemistry from the University of Oxford and pre-venture experience in clinical pathology, virology and drug development.

Heather Roxborough

Oxford Science Enterprises

Heather joined Oxford Science Enterprises in March 2022, a highly experienced venture capitalist, with over 20 years investment and company building experience.

At OSE, she leads the Health Tech team to identify new opportunities, catalyse the creation of transformational new businesses, and scale up the existing portfolio, covering digital health, diagnostics and medical devices.

She joined OSE from Optum Ventures where she was a Partner, responsible for establishing and leading the Global Health Tech investment fund on behalf of Optum, a leading technology-enabled US health services business, part of UnitedHealth Group.

Heather holds a PhD in Clinical Biochemistry from Queen’s University of Belfast.

Ian Downing

Business Growth Fund (BGF)

Ian Downing joined the board of Caristo in 2022 and represents shareholder, BGF – the most active growth investor in the UK and Ireland. Ian has been with BGF since its launch in 2011 and is responsible for BGF’s portfolio of early-stage investments across the UK.  Before BGF, Ian was the CFO of Quotient Sciences, a leading provider of drug development services to the global pharmaceutical sector. He also spent 10 years at 3i, where he completed investments across a range of sectors and represented 3i on the board of over 30 companies, supporting their growth and realising value via trade sale, flotation, and refinancing.

Prof. Charalambos Antoniades

Co-founder & Chief Scientific Officer

MD PhD FESC Pioneered the research on the relationship between adipose tissue and the cardiovascular system, with specific interest in non-invasive imaging of inflammation. This knowledge has been applied in a variety of diseases, ranging from cardiovascular disease to COVID-19. Deputy Head of the Division of Cardiovascular Medicine at the University of Oxford, and Chair of the British Atherosclerosis Society.

Frank Cheng

Chief Executive Officer

Led multiple digital health companies during last twenty years. Held executive positions with publicly traded companies (GE, Roche, Hillrom, Stereotaxis) and led two venture-backed companies as CEO.  Most recently President & CCO of diagnostic company with autonomous AI technology that was FDA-cleared, Medicare-reimbursed, supported by a new Category 1 CPT code, and adopted around the world.

Prof. Keith Channon

Co-founder & Chief Medical Officer

Clinical interventional cardiologist and highly experienced research leader in cardiometabolic disease and risk. Professor at the University of Oxford, with expertise in healthcare innovations in the NHS through NIHR and Director of Academic Health Science Centre.

Prof. Stefan Neubauer

Co-founder & Chief Translational Officer

MD FRCP FACC FMedSci FSCMR Devoted his work to the development and application of novel imaging techniques in MRI and spectroscopy, and most recently in coronary CT. Head of the Division of Cardiovascular Medicine and Director of the Oxford Centre for Clinical Magnetic Resonance Research (OCMR) at the University of Oxford and Past President of the Society for Cardiovascular Magnetic Resonance (SCMR).